BioTime April 6, 2015 Site AdministratorClients No Comments Re-branded as Lineage Cell Therapeutics (NYSE US: LCTX)
Ocata Therapeutics April 6, 2015 Site AdministratorClients No Comments Acquired by Astellas Pharma in 2016 for $379 Million (NY Times’ coverage here)